Interview: Ellson Chen, President & CEO, Vita Genomics, Taiwan
The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science…
Address: 7 Fl., No. 6, Sec. 1, Jung-Shing Road, Wugu Shiang, Taipei, Taiwan
Tel: (+886) 2-8976-9123
Web: http://www.vitagenomics.com/
Vita Genomics, founded in March 2001, has established its headquarter in Taiwan, a marketing office in California, USA, and a wholly owned subsidiary GeneCore in Shanghai, China. Vita Genomics has envisioned itself to be an important player in the healthcare industry by offering advanced and targeted molecular diagnostic products and services, providing more efficient and safer medical solutions, improving the drug development process, and lowering the overall healthcare cost through the pharmacogenomics approaches.Vita Genomics has already built up strong relationships with research institutions and medical organizations throughout Taiwan and China. We are constantly looking for pharmaceutical partners who can benefit from identifying patients for drug responsiveness prior to treatments, partners who would fund expanded pharmacogenomics studies that will enable us to validate the responsiveness of all significant genotypes, and partners who would co-develop DNA-based molecular diagnostic products. Vita Genomics is an active participant in modernizing Taiwan healthcare system. We are establishing the infrastructure needed to add the molecular profile information to the healthcare integrated circuit (IC) card. This is a first step in creating personalized medicine in the future. In addition, Vita Genomics can act as the conduit between the western world and China because we have already established a beachhead in Shanghai.
Vita Genomics follows the high standards of US FDA guidelines in collecting samples in conducting research and clinical studies.Vita Genomics concentrates on the elucidation of the genes and pathways involved in various diseases and on the drug responsiveness of patients in an attempt to improve the healthcare system.
The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science…
BoonHuey Ee, general manager of Merck Biopharma Taiwan, shares her story of joining the affiliate at the beginning of last year and goes on to offer insights on the strengths…
Taiwan’s biotech sector is growing rapidly and increasingly embracing advanced fields such as precision medicine and AI. However, Johnsee Lee, chairman of the Taiwan Bio Industry Organization warns that the island’s…
Rita Huang, dean of the Office of Research and Development and the director of the TMU Research Center for Cell Therapy and Regeneration Medicine highlights the center’s unique capabilities and…
NYMU President Dr Steve Kuo describes the history of the university and transformative period it is currently undergoing. Dr Kuo shares the university’s key strengths and unique strategy to merge…
Dr Michael Chang, founder and chairman of OBI Pharma, shares the history of his company’s beginnings and highlights the current progress of its innovative immune-oncology pipeline. Dr Chang goes on…
Shih-Chung Chen, Minister of Health and Welfare of the Republic of China (Taiwan), gives an update on the Ministry’s current directives under the Biomedical Industry Innovation Program to bolster Taiwan’s…
Dr Hung-Kai Kevin Chen, co-founder and CEO of Elixiron Immunotherapeutics, an innovative rising biotech focused on immunotherapeutic solutions, describes the company’s unique approach to developing new treatment methods for two…
Johnsee Lee, chairman of Taiwan Bio Industry Organization, gives an update on the major developments of the country’s biotech environment over recent years, speaking about its new areas of focus,…
Professor Chi-Hung Lin of NCTU discusses the opportunities and hurdles for unveiling smart healthcare in Taiwan. He also assesses Taiwan’s position in the global race for smart healthcare, and how…
Dar-Bin Shieh, deputy minister of science and technology of the Republic of China (Taiwan), gives an overview of Biomedical Industry Innovation Program, enacted to bolster Taiwan’s biomedical and biotechnology sectors…
Taiwan boasts one of the most sophisticated and comprehensive public health systems in Asia. However, mounting costs and the pressures of a rapidly ageing population mean that the National Health…
Taiwan’s Minister of Economic Affairs, Jong-Chin Shen, outlines the initiatives implemented by the Ministry to help Taiwan’s industries reinforce their competitive advantage. Minister Shen also goes on to explain the…
See our Cookie Privacy Policy Here